IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
J&J reports Q3 2026 results, raises full-year sales and EPS guidanceOct 13Quarterly updateJohnson & Johnson
J&J raises 2026 sales and EPS guidance after strong Q2 resultsJul 15Quarterly updateJohnson & Johnson